Smart foot and ankle brace launches; ConforMIS ends recall investigation;

@FierceMedDev: ICYMI yesterday: Baxter, Boston Sci back TVA in $15M round to ease hemodialysis vascular access. Report | Follow @FierceMedDev

@VarunSaxena2: #AdvaMed15: Director of says local coverage decisions are varying by locality. Not all geographies reimburse Dx tests the same way. | Follow @VarunSaxena2

@EmilyWFierce: Sold on diabetes tech, Joslin tests mobile app for Type 1 patients. FiercePharmaMarketing story | Follow @EmilyWFierce

> Sensoria and Orthotics Holdings are launching a smart foot and ankle brace that's intended to not only help patients walk, but also enable physicians to monitor patient adherence, activity levels and gait parameters. More

> Customized joint implant maker ConforMIS ($CFMS) said that it has finished an investigation of excess moisture and ethylene glycol residue that led to a recall. It said that an independent lab round that the residue posed no significant health hazard. More

> Startup Sebacia has completed enrollment for its U.S. pivotal trial to treat severe acne. Patient follow-up will continue through December. More

> PE firm RoundTable Healthcare Partners has sold intraluminal catheter company Excelsior Medical to ICU Medical for almost $60 million. More

Biotech News

@FierceBiotech: Take the poll: Has the biotech boom come to an end? More | Follow @FierceBiotech

@JohnCFierce: Sold out the Fierce London biotech conference, which is cool. Thank you, U.K. More | Follow @JohnCFierce

> Quartet closes an up-sized A round with a novel approach to pain. News

> Aclaris limps out to a $55M IPO as biotech falters on Wall Street. Report

> Advaxis offers a tardy defense after FDA puts cancer vaccine on hold. Article

Pharma News

@FiercePharma: Something's got to give in India's pharma policy contradictions. FiercePharmaAsia article | Follow @FiercePharma

@EricPFierce: AmerisourceBergen looks for compound interest with its $2.5B deal to buy PharMEDium. FiercePharmaManufacturing story | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: Investors cheer as Arena forces out CEO and cofounder. More | Follow @CarlyHFierce

> U.K. cost gatekeeper says 'OK' to Merck's Keytruda for advanced skin cancer. Story

> Valeant hits back at price-hike critics amid national scrutiny. Article

> Two's company for PCSK9 meds as Praluent, Repatha both nab coverage from top PBM. More

Biotech Research News

> Rutgers researchers make headway with an HDAC inhibitor for Alzheimer's. More

> Alzheimer's: Investigators spotlight a pathway for amyloid beta clearance. Report

> Penn team shines a light on blood disorder. Item

> UCSC team reveals key structural component in telomerase enzyme. Story

> NIH researchers' new mouse model points to a gene therapy for eye disease. Article

Diagnostics News

> Myriad inks coverage deal for prostate cancer test. Item

> Invitae doubles genetic testing menu with cancer, neuromuscular offerings. Report

> Cancer Genetics makes strides in $14M deal for Response Genetics. More

> Invitae doubles genetic testing menu with cancer, neuromuscular offerings. Article

> Illumina expands in China with cancer Dx deal. Story

Pharma Marketing News

> Can Daklinza profit from a set of niche hep C uses? BMS may soon find out. Item

> Bristol-Myers shells out $14.7M in China bribery settlement. More

> British docs weigh in on pharma, and it's no better than most U.S. opinions. Report

> The data difference? Publicis adds data practice to sharpen healthcare media buying and planning. Story

> Glaxo OTC chief: When it comes to consumer health, pharma has the edge. Article